Insulet (PODD) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Insulet Corporation (PODD) PT Raised to $53 at Jefferies Following Solid 4Q
February 28, 2017 9:30 AM ESTJefferies raised its price target on Insulet Corporation (NASDAQ: PODD) to $53.00 (from $45.00) while maintaining a Buy rating.
Analyst Raj Denhoy commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13%... More
